First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial

June 5, 2024

https://www.globenewswire.com/news-release/2024/06/05/2893852/0/en/First-Participants-Vaccinated-in-IMUNON-s-IMNN-101-Phase-1-Clinical-Trial.html

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform

LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform’s potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON’s proprietary PlaCCine® platform is being conducted in healthy volunteers as a seasonal COVID-19 vaccine.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.